603 related articles for article (PubMed ID: 31375080)
1. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Park SH; Belcastro E; Hasan H; Matsushita K; Marchandot B; Abbas M; Toti F; Auger C; Jesel L; Ohlmann P; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2021 Mar; 20(1):65. PubMed ID: 33726768
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice.
Miyata KN; Lo CS; Zhao S; Liao MC; Pang Y; Chang SY; Peng J; Kretzler M; Filep JG; Ingelfinger JR; Zhang SL; Chan JSD
Clin Sci (Lond); 2021 Apr; 135(7):943-961. PubMed ID: 33822013
[TBL] [Abstract][Full Text] [Related]
4. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V
Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Vallon V; Gerasimova M; Rose MA; Masuda T; Satriano J; Mayoux E; Koepsell H; Thomson SC; Rieg T
Am J Physiol Renal Physiol; 2014 Jan; 306(2):F194-204. PubMed ID: 24226524
[TBL] [Abstract][Full Text] [Related]
6. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
Zhang Y; Thai K; Kepecs DM; Gilbert RE
PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
[TBL] [Abstract][Full Text] [Related]
7. A role for tubular Na
Onishi A; Fu Y; Patel R; Darshi M; Crespo-Masip M; Huang W; Song P; Freeman B; Kim YC; Soleimani M; Sharma K; Thomson SC; Vallon V
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F712-F728. PubMed ID: 32893663
[TBL] [Abstract][Full Text] [Related]
8. Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
Castoldi G; Carletti R; Ippolito S; Colzani M; Barzaghi F; Stella A; Zerbini G; Perseghin G; di Gioia CRT
Am J Nephrol; 2020; 51(2):119-129. PubMed ID: 31910407
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension.
Bautista R; Manning R; Martinez F; Avila-Casado Mdel C; Soto V; Medina A; Escalante B
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F127-33. PubMed ID: 14506074
[TBL] [Abstract][Full Text] [Related]
10. Doxazosin down-regulates sodium-glucose cotransporter-2 and exerts a renoprotective effect in rat models of acute renal injury.
Rezq S; Nasr AM; Shaheen A; Elshazly SM
Basic Clin Pharmacol Toxicol; 2020 May; 126(5):413-423. PubMed ID: 31788938
[TBL] [Abstract][Full Text] [Related]
11. Intracellular Angiotensin II Stimulation of Sodium Transporter Expression in Proximal Tubule Cells via AT
Li X; Zhuo J
Cells; 2023 May; 12(11):. PubMed ID: 37296613
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
[TBL] [Abstract][Full Text] [Related]
13. Combining renin-angiotensin system blockade and sodium-glucose cotransporter-2 inhibition in experimental diabetes results in synergistic beneficial effects.
Cruz-López EO; Ye D; Stolk DG; Clahsen-van Groningen MC; van Veghel R; Garrelds IM; Poglitsch M; Domenig O; Alipour Symakani RS; Merkus D; Verdonk K; Jan Danser AH
J Hypertens; 2024 May; 42(5):883-892. PubMed ID: 38088400
[TBL] [Abstract][Full Text] [Related]
14. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice.
Nagata T; Fukuzawa T; Takeda M; Fukazawa M; Mori T; Nihei T; Honda K; Suzuki Y; Kawabe Y
Br J Pharmacol; 2013 Oct; 170(3):519-31. PubMed ID: 23751087
[TBL] [Abstract][Full Text] [Related]
15. Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat.
Bürgelová M; Kramer HJ; Teplan V; Velicková G; Vítko S; Heller J; Malý J; Cervenka L
Kidney Blood Press Res; 2002; 25(4):202-10. PubMed ID: 12424421
[TBL] [Abstract][Full Text] [Related]
16. Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?
Panchapakesan U; Pegg K; Gross S; Komala MG; Mudaliar H; Forbes J; Pollock C; Mather A
PLoS One; 2013; 8(2):e54442. PubMed ID: 23390498
[TBL] [Abstract][Full Text] [Related]
17. Intrarenal Mas and AT
O'Neill J; Healy V; Johns EJ
Exp Physiol; 2017 Dec; 102(12):1700-1715. PubMed ID: 28940861
[TBL] [Abstract][Full Text] [Related]
18. Renal sodium-glucose cotransporter activity and aquaporin-2 expression in rat kidney during chronic nitric oxide synthase inhibition.
Albertoni Borghese MF; Majowicz MP; Ortiz MC; Delgado MF; Sterin Speziale NB; Vidal NA
Nephron Physiol; 2007; 107(3):p77-86. PubMed ID: 17940347
[TBL] [Abstract][Full Text] [Related]
19. Renovascular remodeling and renal injury after extended angiotensin II infusion.
Casare FA; Thieme K; Costa-Pessoa JM; Rossoni LV; Couto GK; Fernandes FB; Casarini DE; Oliveira-Souza M
Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1295-307. PubMed ID: 26962104
[TBL] [Abstract][Full Text] [Related]
20. Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet.
Zeng S; Delic D; Chu C; Xiong Y; Luo T; Chen X; Gaballa MMS; Xue Y; Chen X; Cao Y; Hasan AA; Stadermann K; Frankenreiter S; Yin L; Krämer BK; Klein T; Hocher B
Biomed Pharmacother; 2022 Feb; 146():112606. PubMed ID: 34968924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
